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Abstract 16 
CpG dinucleotides are suppressed in most vertebrate RNA viruses, including HIV-1, 17 
and introducing CpGs into RNA virus genomes inhibits their replication. The zinc-18 
finger antiviral protein (ZAP) binds regions of viral RNA containing CpGs and targets 19 
them for degradation. ZAP does not have enzymatic activity and recruits other cellular 20 
proteins to inhibit viral replication. We found that KHNYN, a protein with no previously 21 
known function, interacts with ZAP. KHNYN overexpression selectively inhibits HIV-1 22 
containing clustered CpG dinucleotides and this requires ZAP and its cofactor 23 
TRIM25. KHNYN requires both its KH-like domain and NYN endonuclease domain for 24 
antiviral activity. Crucially, depletion of KHNYN eliminated the deleterious effect of 25 
CpG dinucleotides on HIV-1 RNA abundance and infectious virus production and also 26 
enhanced the production of murine leukemia virus. Overall, we have identified KHNYN 27 
as a novel cofactor for ZAP to target CpG-containing retroviral RNA for degradation. 28 
  29 
 3 
Introduction 30 
A major component of the innate immune system are cell intrinsic antiviral proteins. 31 
These act at multiple steps in viral replication cycles and some are induced by type I 32 
interferons (Schneider et al., 2014). Many viruses have evolved mechanisms to evade 33 
inhibition by these proteins. First, viruses can encode proteins that counteract specific 34 
antiviral factors. Examples of this mechanism in HIV-1 are the accessory proteins Vif 35 
and Vpu that counteract APOBEC3 cytosine deaminases and Tetherin, respectively 36 
(Malim and Bieniasz, 2012). Second, viral protein or nucleic acid sequences can 37 
evolve to prevent recognition by antiviral factors. The abundance of CpG dinucleotides 38 
is suppressed in many vertebrate RNA virus genomes and when CpGs are 39 
experimentally introduced into picornaviruses or influenza A, viral replication is 40 
inhibited (Atkinson et al., 2014; Burns et al., 2009; Gaunt et al., 2016; Karlin et al., 41 
1994; Tulloch et al., 2014). This shows that CpG suppression in diverse RNA viruses 42 
is required for efficient replication.  43 
 44 
CpG dinucleotides are also suppressed in the HIV-1 genome and multiple studies 45 
have shown that they are deleterious for replication (Antzin-Anduetza et al., 2017; 46 
Kypr et al., 1989; Shpaer and Mullins, 1990; Takata et al., 2017; Theys et al., 2018; 47 
Wasson et al., 2017). Recently, the cellular antiviral protein ZAP was shown to bind 48 
regions of HIV-1 RNA with high CpG abundance and target them for degradation, 49 
which at least partly explains why this dinucleotide inhibits viral replication (Takata et 50 
al., 2017). ZAP (also known as ZC3HAV1) is a component of the innate immune 51 
response targeting viral RNAs in the cytoplasm to prevent viral protein synthesis (Li et 52 
al., 2015). ZAP inhibits the replication of a diverse range of viruses including 53 
retroviruses, alphaviruses, filoviruses, hepatitis B virus and Japanese encephalitis 54 
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virus as well as retroelements (Bick et al., 2003; Chiu et al., 2018; Gao et al., 2002; 55 
Goodier et al., 2015; Mao et al., 2013; Moldovan and Moran, 2015; Muller et al., 2007; 56 
Takata et al., 2017; Zhu et al., 2011). There are two human ZAP isoforms, ZAP-L and 57 
ZAP-S (Kerns et al., 2008). Both isoforms contain a N-terminal RNA binding domain 58 
containing four CCCH-type zinc finger motifs but ZAP-L also contains a catalytically 59 
inactive C-terminal poly(ADP-ribose) polymerase (PARP)-like domain (Chen et al., 60 
2012; Guo et al., 2004; Kerns et al., 2008). Importantly, neither isoform of ZAP has 61 
nuclease activity and it likely recruits other cellular proteins to degrade viral RNAs. 62 
Identifying and characterizing these cofactors for ZAP is essential to understand how 63 
it restricts viral replication. 64 
 65 
ZAP requires the E3 ubiquitin ligase TRIM25 for its antiviral activity against Sindbis 66 
virus and HIV-1 with clustered CpGs (Li et al., 2017; Takata et al., 2017; Zheng et al., 67 
2017). While ZAP has been reported to interact with several components of the 5’-3’ 68 
and 3’-5’ RNA degradation pathways, depletion of these proteins did not substantially 69 
increase infectious virus production for HIV-1 containing clustered CpG dinucleotides 70 
(Goodier et al., 2015; Guo et al., 2007; Takata et al., 2017; Zhu et al., 2011). This 71 
suggests that additional proteins may be required for ZAP to inhibit viral replication. 72 
Herein, we identify KHNYN as a cytoplasmic protein that interacts with ZAP and is 73 
necessary for CpG dinucleotides to inhibit HIV-1 RNA and protein abundance.  74 
 75 
Results 76 
 77 
KHNYN interacts with ZAP and selectively inhibits HIV-1 containing clustered 78 
CpG dinucleotides in a ZAP- and TRIM25-dependent manner. 79 
 5 
To identify candidate interaction partners for ZAP, a yeast two-hybrid screen was 80 
performed for full-length ZAP-S and ZAP-L using prey fragments from a mixed 81 
Pam3CSK4-induced and IFNb-induced human macrophage cDNA library. Candidate 82 
interacting proteins were assigned a Predicted Biological Score (PBS) of A to F 83 
(Formstecher et al., 2005): A = very high confidence in the interaction, B = high 84 
confidence in the interaction and C = good confidence in the interaction. Scores of D 85 
to F are low confidence interactions, non-specific interactions or proven technical 86 
artifacts. For ZAP-S, 11 clones were obtained from 60.4 million tested interactions. 10 87 
of these contained a prey fragment encoding KHNYN (Figure 1) and had a PBS = A. 88 
One clone had an insert encoding MARK3 but this was in the antisense orientation 89 
and therefore did not receive a score. For ZAP-L, two positive clones were analyzed 90 
from 104 million tested interactions. Both of these had an insert encoding KHNYN and 91 
had a PBS = C.  KHNYN has two isoforms (KHNYN-1 and KHNYN-2) that contain a 92 
N-terminal KH-like domain and a C-terminal NYN endoribonuclease domain (Figure 93 
1) (Anantharaman and Aravind, 2006). The selected interaction domain, which is the 94 
amino acid sequence shared by all prey fragments matching KHNYN, comprised 95 
amino acids 572-719 of KHNYN-2 for the clones identified in both screens. A yeast 96 
two-hybrid screen was then performed using the same library with full length KHNYN-97 
2 as the bait. Nine clones were isolated that encode ZAP and these had a PBS = A. 98 
The selected interaction domain was amino acids 4-352, which is present in both 99 
isoforms (Figure 1). Supporting the reproducibility of this interaction, KHNYN has also 100 
been identified as a ZAP-interacting factor in large-scale affinity purification–mass 101 
spectrometry and in vivo proximity-dependent biotinylation (BioID) screens (Huttlin et 102 
al., 2017; Youn et al., 2018). 103 
 104 
 6 
We first confirmed the interaction between ZAP and KHNYN by co-105 
immunoprecipitation and found both KHNYN isoforms interacted with both isoforms of 106 
ZAP (Figure 2A and 2B). This interaction was RNase insensitive (Figure 2C). Since 107 
ZAP mediates degradation of HIV-1 RNAs with clustered CpG dinucleotides in the 108 
cytoplasm (Takata et al., 2017), its cofactors are likely to be localized in this 109 
compartment. Therefore, we analyzed the subcellular localization of KHNYN and 110 
observed that it localizes to the cytoplasm similar to ZAP (Figure 2D). Its localization 111 
was not affected when ZAP was knocked out using CRISPR-Cas9-mediated genome 112 
editing. 113 
 114 
The mechanisms that allow a virus to escape the innate immune response often have 115 
to be inactivated to study the effect of antiviral proteins. For example, HIV-1 Vpu or Vif 116 
have to be mutated to allow Tetherin or APOBEC3 antiviral activity to be analyzed 117 
(Malim and Bieniasz, 2012). Since CpG dinucleotides are suppressed in HIV-1, 118 
endogenous ZAP does not target the wild type virus (Takata et al., 2017). However, a 119 
ZAP-sensitive HIV-1 can be created by introducing CpGs through synonymous 120 
mutations into the env open reading frame in the viral genome. This makes HIV-1 an 121 
excellent system to study the mechanism of action of this antiviral protein because 122 
isogenic viruses can be analyzed that differ only in their CpG abundance and therefore 123 
ZAP-sensitivity (Takata et al., 2017). To determine if KHNYN overexpression inhibited 124 
wild type HIV-1 or HIV-1 with 36 CpG dinucleotides introduced into env nucleotides 125 
86-561 (HIV-1EnvCpG86-561) (Figure 2–figure supplement 1), each isoform was 126 
overexpressed in the context of a single cycle replication assay. As expected, 127 
transfection of the HIV-1EnvCpG86-561 provirus into HeLa cells yielded substantially less 128 
infectious virus than wild type HIV-1, which was accounted for by reduced expression 129 
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of Gag and Env proteins (Figure 2E and 2F). While KHNYN-1 or KHNYN-2 130 
overexpression decreased wild type HIV-1 infectivity by ~5-fold, they decreased HIV-131 
1EnvCpG86-561 infectivity by ~400-fold (Figure 2E). The inhibition of infectivity by KHNYN-132 
1 or KHNYN-2 correlated with decreases in Gag expression, Env expression, and 133 
virion production (Figure 2F). Overall, KHNYN appeared to selectively inhibit HIV-134 
1EnvCpG86-561 infectious virus production.  135 
 136 
We then determined whether ZAP is necessary for KHNYN to inhibit HIV-1 with 137 
clustered CpG dinucleotides. Control or ZAP knockout cells (Figure 3A) were co-138 
transfected with pHIV-1 or pHIV-1EnvCpG86-561 and increasing amounts of pKHNYN-1. 139 
Wild type HIV-1 infectious virus production was not affected by ZAP depletion and HIV-140 
1EnvCpG86-561 infectivity was restored in ZAP knockout cells (Figure 3B, 0 ng of KHNYN-141 
1), confirming that ZAP is necessary to inhibit HIV-1 with CpGs introduced in env 142 
(Takata et al., 2017). At low levels of KHNYN-1 overexpression (such as 62.5 ng), 143 
there was no substantial decrease in infectivity for wild type HIV-1 while HIV-1EnvCpG86-144 
561 infectivity was inhibited in a ZAP-dependent manner (Figure 3B and 4A). The 145 
decrease in infectivity for HIV-1EnvCpG86-561 in control cells transfected with pKHNYN-1 146 
correlated with decreases in Gag expression, Env expression and virion production 147 
(Figure 3C).   148 
 149 
Next, we analyzed how ZAP and KHNYN regulate HIV-1 genomic RNA abundance in 150 
cell lysates and media. As expected (Takata et al., 2017), HIV-1EnvCpG86-561 genomic 151 
RNA abundance was decreased in control cells but was similar to wild type HIV-1 in 152 
ZAP knockout cells (Figure 4B-C, compare GFP samples). In control cells, 62.5 ng of 153 
KHNYN-1 or KHNYN-2 inhibited HIV-1EnvCpG86-561 genomic RNA abundance compared 154 
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to the GFP control (Figure 4B-C). Importantly, KHNYN-1 and KHNYN-2 did not affect 155 
wild type HIV-1 genomic RNA levels and did not substantially inhibit HIV-1EnvCpG86-561 156 
genomic RNA abundance in ZAP knockout cells. This demonstrates that KHNYN 157 
targets HIV-1 RNA containing clustered CpG dinucleotides in a ZAP-dependent 158 
manner.  159 
 160 
TRIM25 is required for ZAP’s antiviral activity, though the mechanism by which it 161 
regulates ZAP is unclear (Li et al., 2017; Zheng et al., 2017). To determine if TRIM25 162 
is necessary for the antiviral activity of KHNYN, 62.5 ng of pKHNYN-1 or pKHNYN-2 163 
was co-transfected with pHIV-1 or pHIV-1EnvCpG86-561 in control and TRIM25 knockout 164 
cells. Both isoforms of KHNYN inhibited HIV-1EnvCpG86-561 much less potently in 165 
TRIM25 knockout cells than control cells and had no effect on wild type HIV-1 in either 166 
cell line (Figure 5A-B). One possible reason that TRIM25 is necessary for KHNYN 167 
antiviral activity could be that it regulates the interaction between ZAP and KHNYN. 168 
We pulled down KHNYN-FLAG and western blotted for ZAP in control and TRIM25 169 
knockdown cells (Figure 5C). Both isoforms of KHNYN pulled down ZAP in both cell 170 
lines, indicating that TRIM25 is not required for the interaction between these proteins. 171 
Interestingly, KHNYN also pulled down TRIM25 in control cells (Figure 5C). Therefore, 172 
we analyzed whether KHNYN interacted with TRIM25 in control and ZAP knockout 173 
cells and observed that both isoforms of KHNYN-FLAG immunoprecipitated TRIM25 174 
in the presence and absence of ZAP (Figure 5D). In sum, KHNYN requires TRIM25 to 175 
inhibit HIV-1 containing clustered CpG dinucleotides, but TRIM25 is not necessary for 176 
the interaction between ZAP and KHNYN. Furthermore, ZAP, KHNYN and TRIM25 177 
appear to be in a complex together. 178 
 179 
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The KH-like and NYN domains are necessary for KHNYN antiviral activity. 180 
As its name implies, KHNYN contains a KH-like domain and a NYN domain (Figure 181 
6A). The KH-like domain differs from canonical KH domains due to a potential small 182 
metal chelating module containing two cysteines and a histidine inserted into the 183 
central region of the domain (Anantharaman and Aravind, 2006). Since this has 184 
diverged substantially from a standard KH domain, it has also been called a CGIN1 185 
domain and is only known to be present in two other proteins (Marco and Marin, 2009). 186 
While most KH domains bind nucleic acids (Nicastro et al., 2015), the insertion in the 187 
KH-like domain in KHNYN may disrupt RNA binding and indicate that it has a different 188 
function. To analyze the functional importance of the KH-like domain, we deleted it 189 
and found that KHNYN-1∆KH and KHNYN-2∆KH had reduced antiviral activity 190 
compared to the wild type protein (Figure 6B-C). These mutant proteins localized to 191 
the cytoplasm and formed foci that were not present for wild type KHNYN-1 or 192 
KHNYN-2 (Figure 6–figure supplement 1).  193 
 194 
NYN domains have endonuclease activity and belong to the PIN nuclease domain 195 
superfamily. There are at least eight human proteins with a potentially active NYN 196 
domain and they have been structurally characterized in several proteins including 197 
ZC3H12A and MARF1 (Matelska et al., 2017; Matsushita et al., 2009; Nishimura et 198 
al., 2018; Xu et al., 2012; Yao et al., 2018). These domains contain a negatively 199 
charged active site with four aspartic acid residues coordinating a magnesium ion, 200 
which activates a water molecule for nucleophilic attack of the phosphodiester group 201 
on the target RNA. Mutation of these acidic residues inhibits nuclease activity by 202 
disrupting the bonds that directly or indirectly interact with the magnesium ion. 203 
ZC3H12A  (also known as MCPIP1 and Regnase) is a RNA binding protein that, 204 
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similar to ZAP, contains a CCCH zinc finger domain and degrades cellular and viral 205 
RNAs (Takeuchi, 2018). The NYN domain in ZC3H12A has 56% identity to the NYN 206 
domain in KHNYN (Figure 6–figure supplement 2A). ZC3H12A containing a D141N 207 
mutation in the NYN domain had decreased endonuclease activity and did not degrade 208 
RNA containing the IL-6 3’ UTR (Matsushita et al., 2009). MARF1 is required for 209 
meiosis and retrotransposon silencing in oocytes and a D426A/D427A mutation 210 
inhibited its endoribonuclease activity (Nishimura et al., 2018; Su et al., 2012). We 211 
made these equivalent mutations in KHNYN (Figure 6A and Figure 6–figure 212 
supplement 2B) and tested their ability to inhibit HIV-1EnvCpG86-561 gene expression and 213 
infectious virus production (Figure 6B-C). KHNYN-1 D443N and KHNYN-2 D484N had 214 
substantially decreased activity against HIV-1EnvCpG86-561. Strikingly, KHNYN-1 215 
D524A/D525A and KHNYN-2 D565A/D566A had no antiviral activity even though they 216 
were expressed at similar levels to the wild type KHNYN. KHNYN proteins with 217 
mutations in the NYN domain localized to the cytoplasm, indicating that disruption of 218 
this domain’s activity did not substantially affect their subcellular localization (Figure 219 
6–figure supplement 1).     220 
 221 
KHNYN is necessary for CpG dinucleotides to inhibit HIV-1 RNA and protein 222 
expression. 223 
To determine if KHNYN is required for CpG dinucleotides to inhibit infectious HIV-1 224 
production, we depleted it using CRISPR-Cas9-mediated genome editing using 225 
single-guide RNAs (sgRNAs) targeting two independent sequences in KHNYN (Figure 226 
7A-C = sgRNA 1, Figure 7–figure supplement 1= sgRNA 2). We were unable to identify 227 
an antibody that detected endogenous KHNYN. However, FLAG-tagged KHNYN-1 228 
and KHNYN-2 were depleted in the bulk population of cells expressing each sgRNA 229 
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as well as two clonal cell lines from each bulk population (Figure 7A and Figure 7–230 
figure supplement 1A). Importantly, when the CRISPR PAM sequence was mutated 231 
in the KHNYN plasmids, KHNYN-1 and KHNYN-2 were no longer depleted. The 232 
relevant region of KHNYN was also sequenced to identify the insertion or deletion in 233 
the bulk populations as well as the clones and genetic alterations that inactive the 234 
protein were identified in each (Figure 7–figure supplement 2). These KHNYN 235 
CRISPR cells were then transfected with pHIV-1 or pHIV-1EnvCpG86-561. In the KHNYN 236 
CRISPR cells, the CpG dinucleotides in HIV-1EnvCpG86-561 no longer inhibited infectious 237 
virus production, Gag expression or Env expression (Figure 7B-C, Figure 7–figure 238 
supplement 1B-C). Wild type HIV-1 Gag expression, Env expression and infectious 239 
virus production was not altered in the KHNYN CRISPR cells compared to the control 240 
cells. Overall, the KHNYN CRISPR cells phenocopied the ZAP CRISPR cells (Figure 241 
7B-C).  242 
 243 
We also analyzed the effect of KHNYN depletion on murine leukemia virus (MLV). 244 
While most retroviruses are suppressed in CpG abundance, the degree of this 245 
suppression varies between the different genera (Berkhout et al., 2002). HIV-1NL4-3 is 246 
highly suppressed (9 CpGs / kb; 0.2 observed/expected), which is conserved in HIV-247 
1 (Berkhout et al., 2002; Kypr et al., 1989; Shpaer and Mullins, 1990). However, the 248 
CpG abundance in MLV is much less suppressed (35 CpGs/kb; 0.5 249 
observed/expected) and ZAP was initially identified as an antiviral protein based on its 250 
ability to bind MLV RNA and target it for degradation (Gao et al., 2002; Guo et al., 251 
2004; Guo et al., 2007). To determine if KHNYN inhibits MLV, control, ZAP and 252 
KHNYN CRISPR cells were co-transfected with pMLV, p2.87 Vpu (which encodes a 253 
highly active HIV-1 Vpu to counteract endogenous Tetherin expression in these cells 254 
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(Neil et al., 2008; Pickering et al., 2014)) and pGFP. MLV Gag expression and virion 255 
production were measured by immunoblotting. Since ZAP is a type I interferon-256 
stimulated gene (Shaw et al., 2017), MLV Gag expression and virion production were 257 
also analyzed after type I interferon treatment. There was a small but reproducible 258 
increase in MLV Gag expression and virion production in the ZAP and KHNYN 259 
CRISPR cells in the absence of type I interferon (Figure 7D). However, after type I 260 
interferon treatment, MLV virion production was decreased to almost undetectable 261 
levels in the control CRISPR cells but was substantially higher in the ZAP and KHNYN 262 
CRISPR cells (Figure 7E).   263 
 264 
The Sindbis virus genome is not substantially depleted in CpG dinucleotides (58 265 
CpGs/kb; 0.9 observed/expected) and is restricted by ZAP (Bick et al., 2003). 266 
However, unlike retroviruses, the predominant ZAP antiviral activity for alphaviruses 267 
is to inhibit viral RNA translation, though there may be an additional effect on RNA 268 
stability (Bick et al., 2003; Kozaki et al., 2015).  As expected (Bick et al., 2003; Kozaki 269 
et al., 2015; Li et al., 2017; Zheng et al., 2017), depletion of TRIM25 and ZAP 270 
substantially increased Sindbis virus replication (Figure 7—figure supplement 3). In 271 
contrast, there was no substantial increase in Sindbis virus replication in the KHNYN 272 
CRISPR cells. Thus, KHNYN appears to be required for the restriction of retroviral 273 
genomes, but not all ZAP-sensitive RNA viruses. 274 
 275 
We then analyzed HIV-1 genomic RNA abundance in the KHNYN CRISPR cells. 276 
Similar to HIV-1 protein expression and infectivity, HIV-1EnvCpG86-561 genomic RNA 277 
abundance was similar in the cell lysate and media to wild type HIV-1 (Figure 8A and 278 
8C), indicating that the CpG dinucleotides no longer inhibited RNA abundance. As 279 
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expected, nef mRNA abundance was not affected by the introduction of CpG 280 
dinucleotides in env or by KHNYN depletion since it is a fully spliced mRNA that does 281 
not contain the introduced CpGs (Figure 8B). The wild type HIV-1 genomic RNA 282 
abundance was not altered in the KHNYN CRISPR cells compared to the control cells, 283 
further showing the specific effect of KHNYN for viral RNA containing CpG 284 
dinucleotides.  285 
 286 
To determine the specificity of the KHNYN knockdown, we titrated CRISPR-resistant 287 
pKHNYN-1 or pKHNYN-2 into the KHNYN CRISPR cells. Even very low levels of 288 
KHNYN-1 or KHNYN-2 restored selective inhibition of HIV-1EnvCpG86-561 in these cells 289 
(Figure 9A-B) and KHNYN-1 was consistently slightly more active than KHNYN-2. This 290 
shows that both isoforms are capable of inhibiting infectious virus production of HIV-1 291 
containing clustered CpG dinucleotides. We also analyzed whether KHNYN with the 292 
KH-like domain deleted or the putative catalytic mutations in the NYN domain could 293 
inhibit HIV-1EnvCpG86-561 infectious virus production in the CRISPR cells. Expression of 294 
31.25 ng of KHNYN-1 in the KHNYN CRISPR cells inhibited HIV-1EnvCpG86-561 (Figure 295 
9C-D) and all of the mutations substantially reduced KHNYN antiviral activity. In sum, 296 
endogenous KHNYN is required for CpG dinucleotides to inhibit HIV-1 infectious virus 297 
production. 298 
 299 
Discussion 300 
Several members of the CCCH zinc finger domain protein family target viral and/or 301 
cellular mRNAs for degradation (Fu and Blackshear, 2017). For example, ZC3H12A 302 
degrades pro-inflammatory cytokine mRNAs and also inhibits the replication of several 303 
viruses, including HIV-1 and hepatitis C virus (Lin et al., 2013; Lin et al., 2014; Liu et 304 
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al., 2013; Matsushita et al., 2009). It contains a CCCH zinc finger domain as well as a 305 
NYN endonuclease domain, which allows it to degrade specific RNAs (Matsushita et 306 
al., 2009; Xu et al., 2012). ZAP has four CCCH zinc finger domains and specifically 307 
interacts with CpG dinucleotides in RNA (Gao et al., 2002; Guo et al., 2004; Takata et 308 
al., 2017). However, it does not contain nuclease activity. While ZAP has been 309 
reported to directly or indirectly interact with components of the 5’-3’ and 3’-5’ 310 
degradation pathways including DCP1-DCP2, XRN1, PARN and the exosome, 311 
knockdown of several proteins in these pathways did not substantially rescue 312 
infectious virus production of HIV-1 containing clustered CpG dinucleotides (Goodier 313 
et al., 2015; Guo et al., 2007; Takata et al., 2017; Zhu et al., 2011). Therefore, we 314 
hypothesized that ZAP may interact with additional unidentified proteins that regulate 315 
viral RNA degradation.  316 
 317 
Herein, we have identified that KHNYN is an essential ZAP cofactor that inhibits HIV-318 
1 gene expression and infectious virus production when the viral RNA contains 319 
clustered CpG dinucleotides. KHNYN overexpression inhibits genomic RNA 320 
abundance, Gag expression, Env expression and infectious virus production for HIV-321 
1 containing clustered CpG dinucleotides. This activity requires ZAP and TRIM25. 322 
Furthermore, depletion of KHNYN using CRISPR-Cas9 specifically increased 323 
genomic RNA abundance, Gag expression, Env expression and infectious virus 324 
production for HIV-1 containing clustered CpG dinucleotides. This indicates that 325 
KHNYN is essential for CpG dinucleotides to inhibit infectious virus production. 326 
Similarly, KHNYN depletion increased MLV Gag expression and virion production. 327 
However, Sindbis virus replication was not substantially increased in the KHNYN 328 
knockout cells. The difference between the requirement for KHNYN to inhibit 329 
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retroviruses versus Sindbis virus may be because the antiviral effect for retroviruses 330 
is predominantly at the level of RNA stability and for alphaviruses it is predominately 331 
at the level of translation (Bick et al., 2003; Gao et al., 2002; Guo et al., 2004; Guo et 332 
al., 2007; MacDonald et al., 2007). A mechanistic explanation for why the major 333 
antiviral effect of ZAP appears to be promoting RNA degradation for some viruses and 334 
inhibiting translation for other viruses remains unclear, though ZAP has been reported 335 
to inhibit translation initiation by interfering with the interaction between eIF4A and 336 
eIF4G (Zhu et al., 2012). Therefore, KHNYN may not be required for ZAP to inhibit 337 
translation. 338 
 339 
We hypothesize that a complex containing ZAP and KHNYN binds HIV-1 CpG-340 
containing RNA. ZAP and KHNYN could directly interact to form a heterodimer or there 341 
could be other factors mediating this interaction. The interaction between ZAP and 342 
KHNYN has been detected using several different assays including yeast-two-hybrid, 343 
co-immunoprecipitation, affinity purification–mass spectrometry (Huttlin et al., 2017) 344 
and BioID (Youn et al., 2018). If there is an unknown factor mediating this interaction, 345 
it would have to present in the yeast-two-hybrid assay. It remains unclear how TRIM25 346 
regulates ZAP, but it is not required for ZAP and KHNYN to interact. Interestingly, 347 
TRIM25 co-immunoprecipitates with KHNYN and the ZAP antiviral complex may 348 
simultaneously consist of all three proteins. ZAP and TRIM25 are interferon-stimulated 349 
genes while KHNYN is not induced by interferon in human cells (Shaw et al., 2017). 350 
Whether KHNYN is regulated by type I interferons or viral infection in a different way, 351 
such as post-translational modification, is not known. 352 
 353 
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The zinc finger RNA binding domains in ZAP could target KHNYN to CpG regions in 354 
viral RNA. This would allow the endonuclease domain in KHNYN to cleave this RNA, 355 
thereby inhibiting viral RNA abundance. Conceptually, the ZAP-KHNYN complex 356 
could function similarly to ZC3H12A, but with the RNA binding and endonuclease 357 
domains divided between the two proteins. The NYN domain in KHNYN could cleave 358 
HIV-1 RNA containing CpG dinucleotides similar to how ZC3H12A cleaves a specific 359 
site in the 3’ UTR of the IL-6 mRNA (Matsushita et al., 2009). While we do not yet have 360 
evidence that the NYN domain in KHNYN is an active endonuclease domain, it is 361 
highly conserved with the active NYN domain in ZC3H12A and is required for KHNYN 362 
antiviral activity. Strikingly, mutation of two conserved aspartic acid residues in the 363 
NYN domain predicted to coordinate a magnesium ion necessary for nucleophilic 364 
attack of the target RNA eliminated KHNYN antiviral activity. However, biochemical 365 
and structural studies will be necessary to determine the specific nature of the 366 
interaction between ZAP, KHNYN, TRIM25 and RNA and how these interactions 367 
promote viral RNA degradation.  368 
 369 
An increasingly common theme for RNA decay is that endonucleic and exonucleic 370 
degradation pathways work together to fully degrade RNAs. For example, nonsense-371 
mediated decay (NMD) targets mRNAs that do not efficiently terminate translation at 372 
the stop codon and uses up to four mechanisms to degrade these mRNAs: 373 
endonucleic cleavage, deadenylation, decapping and exonucleic degradation (Lykke-374 
Andersen and Jensen, 2015).  In this pathway, the endonuclease SMG6 interacts with 375 
the core regulatory protein UPF1 and cleaves mRNA near a premature termination 376 
codon. The 5’ and 3’ cleavage fragments are then degraded by the 5’-3’ exonuclease 377 
XRN1 and the 3’-5’ exonuclease exosome complex. The CCR4–NOT deadenylase 378 
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complex and DCP1-DCP2 decapping complex are recruited by proteins in the NMD 379 
complex including UPF1, SMG5, SMG7 and PNRC2. Similarly, the 5’-3’ and 3’-5’ 380 
degradation pathway components previously shown to interact with ZAP could work 381 
in conjunction with KHNYN-mediated endonucleic decay (Goodier et al., 2015; Guo et 382 
al., 2007; Zhu et al., 2011). In this model, KHNYN would initiate cleavage of the viral 383 
RNA and the exonucleic pathways would then degrade the resulting RNA fragments. 384 
Identifying the full complement of ZAP-interacting factors and characterizing how 385 
these target viral RNAs for degradation will be an exciting area of future investigation. 386 
 387 
Another important area of future research will be to determine how KHNYN and other 388 
cellular proteins that contain an NYN endonuclease domain inhibit the replication of 389 
different viruses in different cell types with and without interferon treatment. The 390 
interferon-stimulated gene N4BP1, which is a KHNYN paralog (Anantharaman and 391 
Aravind, 2006), was recently identified to genetically interact with ZAP in a CRISPR-392 
based screen to identify interferon-induced antiviral proteins targeting HIV-1 (OhAinle 393 
et al., 2018). In the monocytic THP-1 cell line, depletion of N4BP1 led to a small 394 
increase in wild type HIV-1 replication. However, N4BP1 depletion did not inhibit 395 
replication of the alphavirus Semliki Forest virus, indicating that it may have a virus 396 
specific effect. While ZAP inhibits a range of viruses in different cell types, it remains 397 
unknown whether its cofactor requirements are cell type dependent. In this study, we 398 
have analyzed the antiviral activity of ZAP and KHNYN on HIV-1 and MLV in HeLa 399 
cells, but the role of NYN domain-containing proteins in targeting viral RNAs for 400 
degradation may be an important component of the antiviral innate immune response 401 
in a variety of cell types. It will also be interesting to determine if proteins containing 402 
an endonuclease domain other than KHNYN interact with CCCH zinc finger proteins 403 
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to mediate antiviral activity. There are 57 human CCCH zinc finger proteins (Fu and 404 
Blackshear, 2017). At least 15 of these proteins are known to promote RNA decay 405 
and, including ZAP, six human CCCH zinc finger proteins are antiviral (Fu and 406 
Blackshear, 2017). Identifying the full complement of CCCH zinc finger proteins that 407 
inhibit viral replication and determining whether they require proteins containing 408 
endonuclease domains such as KHNYN or N4BP1 for this activity will increase our 409 
understanding of antiviral responses targeting viral RNA. 410 
 411 
Materials and Methods 412 
 413 
Plasmids 414 
All primers were ordered from Eurofins. Polymerase chain reactions (PCR) for cloning 415 
steps were performed with Phusion High Fidelity polymerase (New England Biolabs). 416 
KHNYN-2 (NM_001290256) was synthesized by GenScript. KHNYN-1 was cloned by 417 
amplifying the nucleotides 123-2157 from KHNYN-2 and sub-cloning the PCR product 418 
into the pcDNA3.1 (+) backbone using the HindIII site in the vector and SbfI site in the 419 
KHNYN open reading frame. KHNYN-1 ΔKH, D443N, D524A/D525A, -CRG1, -CRG2 420 
and KHNYN-2 ΔKH, D484N, D565A/D566A, -CRG1, -CRG2 were generated via 421 
overlap extension PCR and subsequently sub-cloning the PCR product into the 422 
pcDNA3.1 (+) backbone as described above. pGFP-FLAG was cloned by amplifying 423 
GFP from pcDNA3.1-GFP(Swanson et al., 2010) and cloning it into pcDNA3.1. 424 
Diagnostic restriction enzyme digestion and DNA sequencing (Eurofins, Genewiz) was 425 
used to ensure the correct identity of modified sequences inserted into plasmids.  426 
 427 
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pHIV-1NL4-3 contains the HIV-1 provirus in the pGL4 vector (Antzin-Anduetza et al., 428 
2017). To generate HIV-1EnvCpG86-561, we synthesized a HIV-1NL4-3 EcoRI/StuI DNA 429 
fragment with synonymous mutations that inserted 36 CpG dinucleotides into env 430 
(Figure 2–figure supplement 1). This DNA fragment was digested with EcoRI and StuI 431 
and inserted into the corresponding sites of pHIV-1NL4-3. pMLV is pNCS, which 432 
contains the Moloney murine leukemia virus provirus DNA (Yueh and Goff, 2003). 433 
pCR3.1 2.87 Vpu contains the HA-tagged codon-optimized HIV-1 Vpu 2.87 (Pickering 434 
et al., 2014). 435 
 436 
Cell lines 437 
HeLa and HEK293T cells were obtained from the ATCC and were maintained in high 438 
glucose DMEM supplemented with GlutaMAX, 10% fetal bovine serum, 20µg/mL 439 
gentamicin or 100 U/ml penicillin and 100 μg/ml streptomycin and incubated with 5% 440 
CO2 at 37oC. BHK-21 cells were obtained from ATCC and were maintained in GMEM 441 
supplemented with 10% fetal bovine serum, 10% tryptose phosphate broth, and 442 
penicillin/streptomycin. Their identity has not been authenticated and they are 443 
routinely tested for mycoplasma contamination with all tests negative. CRISPR guides 444 
targeting the firefly luciferase gene, lacZ gene, human TRIM25, ZAP (also known as 445 
ZC3HAV1), and KHNYN genes were cloned into BsmBI restriction enzyme sites in the 446 
lentiviral vector genome plasmid lentiCRISPRv2(Sanjana et al., 2014). The CRISPR 447 
guide sequences are: LacZ-G1: 5’- CGA TTA AGT TGG GTA ACG CC -3’, Luciferase-448 
G1: 5’-CTT TAC CGA CGC ACA TAT CG-3’, TRIM25-G1: 5’-GAG CCG GTC ACC 449 
ACT CCG TG -3’, ZAP-G1: 5’- ACT TCC ATC TGC CTT ACC GG -3’, KHNYN-G1: 5’-450 
GGG GGT GAG CGT CCT TCC GA-3’, KHNYN-G2: 5’-CAG ACA CCG CAA AGC 451 
GAT CT-3’. LentiCRISPR vectors encoding guides RNA targeting KHNYN or LacZ 452 
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were produced in HEK293T cells seeded in a 10cm dish and transfected using 100 ul 453 
PEI with 8µg of lentiCRISPRv2-Guide, 8µg of pCRV1-HIV-Gag Pol (Neil et al., 2008) 454 
and 4µg of pCMV-VSV-G (Neil et al., 2008). Lentiviral vectors encoding guide RNAs 455 
targeting ZAP or TRIM25 were produced by transfecting HEK293T cells seeded in a 456 
6-well plate using 10 µl PEI with 0.5µg pVSV-G (Fouchier et al., 1997), 1.0 µg 457 
pCMV∆R8.91 (Zufferey et al., 1997), and 1.0 µg LentiCRISPRv2-Guide. Virus 458 
containing supernatant was harvested 48-hr after transfection, rendered cell-free via 459 
filtration through 0.45 µM filters (Millipore) and used to transduce HeLa or HEK293T 460 
cells followed by selection in puromycin.  461 
 462 
Yeast two-hybrid screen 463 
The yeast two-hybrid screen was performed by Hybrigenics Services, S.A.S., Paris, 464 
France (http://www.hybrigenics-services.com). Full length ZAP-S, ZAP-L and KHNYN-465 
2 were PCR-amplified and cloned into pB27 as a C-terminal fusion to LexA . These 466 
constructs were used as a bait to screen a random-primed Induced Macrophages 467 
cDNA library constructed into pP6. pB27 and pP6 derive from the original pBTM116 468 
(Vojtek and Hollenberg, 1995) and pGADGH (Bartel and Fields, 1995) plasmids, 469 
respectively. Clones were screened using a mating approach with YHGX13 (Y187 470 
ade2-101::loxP-kanMX-loxP, mata) and L40∆Gal4 (mata) yeast strains as previously 471 
described (Fromont-Racine et al., 1997). His+ colonies were selected on a medium 472 
lacking tryptophan, leucine and histidine. Because KHNYN-2 had some autoactivating 473 
activity, the selection medium was supplemented with 10 mM 3-Aminotriazol.  474 
 475 
The prey fragments of the positive clones were amplified by PCR and sequenced at 476 
their 5’ and 3’ junctions. The resulting sequences were used to identify the 477 
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corresponding interacting proteins in the GenBank database (NCBI) using a fully 478 
automated procedure. A confidence score (PBS, for Predicted Biological Score) was 479 
attributed to each interaction as previously described (Formstecher et al., 2005). The 480 
PBS relies on two different levels of analysis. First, a local score takes into account 481 
the redundancy and independency of prey fragments, as well as the distribution of 482 
reading frames and stop codons in overlapping fragments. Second, a global score 483 
takes into account the interactions found in all the screens performed at Hybrigenics 484 
using the same library. This global score represents the probability of an interaction 485 
being nonspecific. The scores were divided into six categories: A (highest confidence) 486 
to D (lowest confidence) plus category E that demarcates interactions involving highly 487 
connected prey domains previously found several times in screens performed on 488 
libraries derived from the same organism and category F that indicates highly 489 
connected domains that have been confirmed as false-positives. The PBS scores have 490 
been shown to positively correlate with the biological significance of interactions (Rain 491 
et al., 2001; Wojcik et al., 2002). 492 
 493 
Transfections 494 
HeLa and HEK293T cells were grown to 70% confluence in six-well plates. HeLa cells 495 
were transfected according to the manufacturer’s instructions using TransIT®-LT1 496 
(Mirus) at the ratio of 3 µL TransIT®- LT1 to 1 µg DNA. HEK293T cells were 497 
transfected according to the manufacturer’s instructions using PEI (1mg/mL) (Sigma-498 
Aldrich) at the ratio of 4 µL PEI to1 µg DNA. For the HIV-1 experiments, 0.5µg pHIV-499 
1 and the designated amount of pKHNYN-FLAG, pGFP-FLAG or pGFP (Swanson et 500 
al., 2010) were transfected for a total of 1µg DNA. For the MLV experiments, 0.65 µg 501 
pMLV, 0.25 µg pCR3.1 2.87 Vpu and 0.10 µg pGFP were transfected. The transfection 502 
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medium was replaced with fresh medium after a 6-hr incubation (HEK293T) or 24-hr 503 
incubation (HeLa). 504 
 505 
Analysis of protein expression by immunoblotting 506 
HeLa cells were seeded on 6-well plates and transfected the following day with as 507 
described above. Approximately 48-hr post-transfection, HeLa cells were lysed in 508 
radioimmunoprecipitation assay (RIPA) buffer (150 mM NaCl, 1 mM EDTA, 1% Triton 509 
X-100, 1% sodium deoxycholate, 0.1% SDS, 10 mM Tris–HCl pH 7.5) supplemented 510 
with complete protease inhibitor (Roche) and sheared using a 0.5G needle. Media was 511 
filtered through a 0.45 µM filter and virions were pelleted for 2-hr at 20,000 x g through 512 
a 20% sucrose cushion in phosphate-buffered saline (PBS) solution. The pellet was 513 
resuspended in 2X loading buffer (60 mM Tris–HCl pH 6.8, 2% sodium dodecyl sulfate 514 
(SDS), 10% glycerol, 10% β-mercaptoethanol, 0.1% bromophenol blue). Cell lysates 515 
and virions were resolved by 10 % SDS-polyacrylamide gel electrophoresis (PAGE), 516 
transferred to a nitrocellulose membrane (GE Healthcare) and blocked in 1% non-fat 517 
milk in PBS with 0.1% Tween 20 (Fischer Bioreagents). Primary antibodies were 518 
incubated for 2 hours at room temperature. After washing in PBS, blots were incubated 519 
for 1 hour with the appropriate secondary antibody. Bound antibodies were visualized 520 
on the LI-CORTM (Odyssey Fc) measuring the immunofluorescence or using 521 
Amersham ECL Prime Western Blotting Detection reagent (GE Lifesciences) for HRP-522 
linked antibodies using an ImageQuantTM (LAS4000 Mini). For the co-523 
immunoprecipitation experiments, lysates were resolved using precast Mini-524 
PROTEAN TGX gels 8-16% gradient gels (Bio-Rad) and transferred to nitrocellulose 525 
membranes (Bio-Rad). Antibodies used in study were 1:50 HIV- 1 anti-526 
p24Gag(Chesebro et al., 1992), 1:3000 anti-HIV-1 gp160/120 Rabbit (ADP421; 527 
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Centralized Facility for AIDS Reagents (CFAR)), 1:10,0000 anti-HSP90 (sc7947, 528 
Santa Cruz Biotechnology), 1:5000 anti-HSP90 Rabbit (GeneTex, GTX109753), 529 
1:4000 anti-HSP90 Mouse (SantaCruz, sc-515081), 1:5000 anti-ZAP (Abcam, 530 
ab154680), 1:1000 anti-β-Actin Mouse (Sigma, A2228), 1:2500 anti-DYKDDDDK 531 
(Rabbit) (Cell Signaling, 14793), 1:2500 anti-FLAG (Mouse) (Sigma, F1804), 1:2500 532 
anti-FLAG (Rabbit) (Sigma, F7425), 1:10000 anti-TRIM25 (Abcam, ab167154), 533 
1:10000 anti-MLV p30 (Rat) (ATCC CRL-1912) (Chesebro et al., 1983), 1:10,000 534 
Dylight™ 800- conjugated secondary antibodies (Cell Signaling Technology, 5151S 535 
and 5257S), 1:5000 anti-rabbit HRP (Cell Signaling Technology, 7074), 1:5000 anti-536 
mouse HRP (Cell Signaling Technology, 7076), 1:4000 anti-rabbit IRDye 800CW (LI-537 
COR, 926-32211) or 1:4000 anti-mouse IRDye 680RD (LI-COR, 926-68070).  538 
 539 
TZM-bl infectivity assay 540 
Media was recovered approximately 48-hr post-transfection and cell-free virus stocks 541 
were generated by filtering the media through 0.45 µM filters (Millipore). The TZM-bl 542 
indicator cell line was used to quantify the amount of infectious virus (Derdeyn et al., 543 
2000; Platt et al., 1998; Wei et al., 2002). TZM-bl cells were seeded at 70% confluency 544 
in 24- well plates and infected by overnight incubation with virus stocks. 48-hr post 545 
infection, the cells were lysed and infectivity was measured by analyzing β-546 
galactosidase expression using the Galacto-Star™ System following manufacturer’s 547 
instructions (Applied Biosystems). β-galactosidase activity was quantified as relative 548 
light units per second using a PerkinElmner Luminometer. 549 
 550 
Immunoprecipitation assays 551 
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HEK293T cells in 6-well plates were transfected with 800ng of pKHNYN-1-FLAG, 552 
pKHNYN-2-FLAG, pGFP-FLAG as a control using 3 µL TransIT®-LT1 per 1µg of DNA 553 
added. For the experiments in which lysates were treated with Ribonuclease A (RNase 554 
A), 500ng of pHA-ZAP-L (Kerns et al., 2008) was also added. The cells were lysed on 555 
ice in lysis buffer (0.5% NP-40, 150mM KCl, 10mM HEPES pH 7.5, 3mM MgCl2) 556 
supplemented with complete EDTA-free Protease inhibitor cocktail tablets (Sigma-557 
Aldrich), 10mM N-Ethylmaleimide (Sigma-Aldrich) and PhosSTOP tablets (Sigma-558 
Aldrich). The lysates were sonicated and then centrifugated at 20,000 x g for 5 minutes 559 
at 4°C. 50µl of the post-nuclear supernatants was saved as the Input lysate and 450µl 560 
were incubated with either 18µg of anti-Flag antibody (Sigma-Aldrich, F7425) or 561 
4.275µg of anti-ZAP antibody (Abcam) for one hour at 4°C with rotation. Protein G 562 
Dynabeads (Invitrogen) were then added and incubated for three hours at 4°C with 563 
rotation. The lysates were then washed 4 times with wash buffer (0.05% NP-40, 564 
150mM KCl, 10mM HEPES pH 7.5, 3mM MgCl2) before bound proteins were eluted 565 
with Laemmli buffer and boiled for 10 minutes. When indicated, RNase A (Sigma-566 
Aldrich) was added to the post-nuclear supernatant and incubated for 30 minutes at 567 
37°C. Protein expression was analyzed via Western blot as described above.  568 
 569 
RNA Purification and quantitative RT-PCR 570 
Total RNA was isolated from transfected HeLa cells using a QIAGEN RNeasy kit 571 
accordingly with the manufacturer’s instructions. Viral RNA was extracted from cell 572 
supernatants using a QIAGEN QIAamp Viral mini kit accordingly with the 573 
manufacturer’s instructions. 500 ng of purified cellular RNA was reverse transcribed 574 
using random hexamer primers and a High Capacity cDNA Reverse Transcription kit 575 
(Applied Biosystems). Quantitative PCR was performed using a QuantiStudio 5 576 
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System (Thermo Fisher). For genomic RNA and nef mRNA in the cell lysate, the  HIV-577 
1 RNA abundance was normalized to GAPDH levels using the GAPDH Taqman Assay 578 
(Applied Biosystems, Cat# Hs99999905_m1). For the genomic RNA in the media, 579 
absolute quantification was determined using a standard curve of the HIV-1 provirus 580 
DNA plasmid. The genomic RNA primers were GGCCAGGGAATTTTCTTCAGA / 581 
TTGTCTCTTCCCCAAACCTGA (forward/reverse) and the probe was FAM-582 
ACCAGAGCCAACAGCCCCACCAGA-TAMRA. The nef mRNA primers were 583 
GGCGGCGACTGGAAGAAGC / GATTGGGAGGTGGGTTGCTTTG-3’ 584 
(forward/reverse) (Jablonski and Caputi, 2009). 585 
 586 
Microscopy 587 
Cells were seeded on 24-well plates on coverslips pre-treated with poly-lysine. 588 
HEK293T cells expressing a control guide RNA targeting the LacZ gene or a guide 589 
RNA targeting ZAP were transfected with 250ng of pKHNYN-FLAG. 24 hours post-590 
transfection, the cells were fixed with 4% paraformaldehyde for 15 minutes at room 591 
temperature, washed with PBS, and then washed with 10mM glycine. The cells were 592 
then permeabilized for 15 minutes with 1% BSA and 0.1% Triton-X in PBS. Mouse 593 
anti-FLAG (1:500) and rabbit anti-ZAP (1:500) antibodies were diluted in PBS/0.01% 594 
Triton-X and the cells were stained for one hour at room temperature. The cells were 595 
then washed 3 times in PBS/0.01% Triton-X and incubated with Alexa Fluor 594 anti-596 
mouse and Alexa Fluor 488 anti-rabbit antibodies (Molecular Probes, 1:500 in 597 
PBS/0.01% Triton-X) for 45 minutes in the dark. Finally, the coverslips were washed 598 
three times with PBS/0.01% Triton-X and then mounted on slides with Prolong 599 
Diamond Antifade Mountant with DAPI (Invitrogen). Imaging was performed on a 600 
Nikon Eclipse Ti Inverted Microscope, equipped with a Yokogawa CSU/X1-spinning 601 
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disk unit, under 60-100x objectives and laser wavelengths of 405nm, 488nm and 602 
561nm. Image processing and co-localization analysis was performed with NIS 603 
Elements Viewer and Image J (Fiji) software. 604 
 605 
Analysis of CpG frequency in HIV-1, MLV and Sindbis virus 606 
The “analyze base composition” tool in MacVector was used to calculate the CpG 607 
frequencies for the HIV-1NL4-3 (NCBI accession number M19921) genomic RNA, MLV 608 
genomic RNA (J02255) and Sindbis virus (NC_001547). The CpG frequencies were 609 
calculated using the following formula:  number of CpG occurrences / (frequency of C 610 
* frequency of G) where frequency of the base is the number of occurrences of the 611 
base / total number of bases in sequence. 612 
 613 
Sindbis virus replication assays 614 
Sindbis virus (SINV), a kind gift from Penny Powell (University of East Anglia), was 615 
expanded and titrated in BHK-21 cells (Mazzon et al., 2018). Control, ZAP, TRIM25 616 
or KHNYN HeLa cells were plated at 100,000 cells/well in 12 well plates. The following 617 
day, the cells were infected with Sindbis virus at a multiplicity of infection of 0.005 618 
pfu/cell. After 90 mins, the infectious media was removed, the cells were washed once 619 
with PBS and then incubated with 1 ml of media. The media from the infected cells 620 
was harvested at 8, 16, 24 and 32 hours post infection. 100ul of serial diluted media 621 
from the cells (from 10-1 to 10-8) were added onto BHK-21 cells in 96 well plates (8,000 622 
cells/well plated the previous day). After 90 minutes, the media was removed and 623 
replaced with fresh media. An MTT assay was carried out on each plate 24h later. 624 
Briefly, 20µl of 50 mg/ml Thiazolyl Blue Tetrazolium Bromide in PBS were added onto 625 
the cell media for 2h at 37 oC, after which the supernatant is removed and replaced 626 
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with 40µl of a 1:1 solution of isopropanol and DMSO. 20 minutes later, 35 µl of the 627 
supernatant are transferred onto a 96 well plate and signal read at 570 nm.  Values 628 
from this assay were used to determine the TCID50 and pfu/ml. 629 
 630 
Statistical analysis 631 
Statistical significance was determined using unpaired two-tailed t tests calculated 632 
using Microsoft excel software. Data are represented as mean ± SD. Significance was 633 
ascribed to p values p < 0.05. 634 
 635 
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MAIN FIGURE LEGENDS  870 
Figure 1. KHNYN is a ZAP-interacting factor identified by yeast two-hybrid 871 
screening. 872 
A yeast two-hybrid screen for ZAP-S and ZAP-L interacting factors identified a region 873 
in KHNYN-1 and KHNYN-2. The selected interaction domain (SID) is the amino acid 874 
sequence shared by all prey fragments and is shown in magenta. A reciprocal yeast 875 
two-hybrid screen using KHNYN-2 as the bait identified a region in ZAP-S and ZAP-876 
L. The SID is shown in red.    877 
 878 
Figure 2. KHNYN interacts with ZAP and selectively inhibits HIV-1 containing 879 
clustered CpG dinucleotides. 880 
(A) Lysates of HEK293T cells transfected either with pGFP-FLAG, pKHNYN-1-FLAG 881 
or pKHNYN-2-FLAG were immunoprecipitated with an anti-ZAP antibody. Post-882 
nuclear supernatants and immunoprecipitation samples were analyzed by 883 
immunoblotting for Hsp90, KHNYN-FLAG and ZAP. * indicates a non-specific band. 884 
(B) Lysates of HEK293T cells transfected either with pGFP-FLAG, pKHNYN-1-FLAG 885 
or pKHNYN-2-FLAG were immunoprecipitated with an anti-FLAG antibody. Post-886 
nuclear supernatants and immunoprecipitation samples were analyzed by 887 
immunoblotting for HSP90, KHNYN-FLAG and ZAP. * indicates a non-specific band. 888 
(C) Lysates of HEK293T cells transfected with pZAP-L and either pGFP-FLAG, 889 
pKHNYN-1-FLAG or pKHNYN-2-FLAG were treated with RNase and then 890 
immunoprecipitated with an anti-FLAG antibody. Post-nuclear supernatants and 891 
immunoprecipitation samples were analyzed by immunoblotting for HSP90, KHNYN-892 
FLAG and ZAP. * indicates a non-specific band. 893 
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(D) Panels show representative fields for the localization of KHNYN-1-FLAG or 894 
KHNYN-2-FLAG and endogenous ZAP in either 293T Control CRISPR cells 895 
expressing a guide RNA targeting LacZ or 293T ZAP guide 1 (ZAP-G1) CRISPR cells. 896 
Cells were stained with an anti-FLAG antibody (red), anti-ZAP antibody (green) and 897 
DAPI (blue). The scale bar represents 10 µM.  898 
(E-F) HeLa cells were transfected with 500 ng pHIV-1 or pHIV-1EnvCpG86-561 and 500 ng 899 
of pGFP-FLAG, pKHNYN-1-FLAG or pKHNYN-2-FLAG. See also Figure 2–figure 900 
supplement 1. Culture supernatants were used to infect TZM-bl reporter cells to 901 
measure infectivity (E). The bar charts show the average values of three independent 902 
experiments normalized to the value obtained for HeLa cells co-transfected with pHIV-903 
1 and pGFP-FLAG. Data are represented as mean ± SD. *p < 0.05 as determined by 904 
a two-tailed unpaired t-test. p-values for GFP verses KHNYN-1 and KHNYN-2 for wild 905 
type HIV-1 are 2.76 x 10-9  and 2.20 x 10-6 respectively. p-values for GFP verses 906 
KHNYN-1 and KHNYN-2 for HIV-1EnvCpG86-561 are 1.50 x 10-3 and 1.51 x 10-3, 907 
respectively. Gag expression in the media as well as Gag, Hsp90, Env, Actin, KHNYN-908 
FLAG and GFP-FLAG expression in the cell lysates was detected using quantitative 909 
immunoblotting (F).  910 
 911 
Figure 3. ZAP is required for KHNYN to inhibit infectious virion production for 912 
HIV-1 with clustered CpG dinucleotides. 913 
(A) ZAP, TRIM25 and Actin expression in HeLa cells, HeLa Control CRISPR cells 914 
(expressing a guide RNA targeting the firefly luciferase gene), HeLa ZAP CRISPR 915 
guide 1 (ZAP-G1) cells and HeLa TRIM25 CRISPR guide 1 (TRIM25-G1) cells were 916 
detected using quantitative immunoblotting. 917 
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(B-C) HeLa Control CRISPR cells or ZAP-G1 CRISPR cells were transfected with 500 918 
ng pHIV-1 or pHIV-1EnvCpG86-561 and 500 ng of pGFP-FLAG or 31.25 ng, 62.5 ng, 125 919 
ng, 250 ng or 500 ng pKHNYN-1-FLAG plus the amount of pGFP-FLAG required to 920 
make 500 ng total. Culture supernatants from the cells were used to infect TZM-bl 921 
reporter cells (B). Each point shows the average value of three independent 922 
experiments normalized to the value obtained for HeLa Control CRISPR cells co-923 
transfected with pHIV-1 and pGFP-FLAG. Data are represented as mean ± SD. Gag 924 
expression in the media as well as Gag, Hsp90, Env, Actin, KHNYN-FLAG and GFP-925 
FLAG expression in the cell lysates was detected using quantitative immunoblotting 926 
(C). 927 
 928 
Figure 4. ZAP is required for KHNYN to inhibit genomic RNA abundance for HIV-929 
1 with clustered CpG dinucleotides. 930 
(A-C) HeLa Control CRISPR cells or ZAP-G1 CRISPR cells were transfected with 500 931 
ng pHIV-1 or pHIV-1EnvCpG86-561 and 500 ng of pGFP-FLAG or 62.5 ng pKHNYN-1/2-932 
FLAG plus 437.5 ng of pGFP-FLAG. Culture supernatants from the cells were used to 933 
infect TZM-bl reporter cells (A). The bar chart shows the average value of five 934 
independent experiments normalized to the value obtained for HeLa Control CRISPR 935 
cells co-transfected with pHIV-1 and pGFP-GFP. Data are represented as mean ± SD. 936 
*p < 0.05 as determined by a two-tailed unpaired t-test. p-values for GFP verses 937 
KHNYN-1 and KHNYN-2 for HIV-1EnvCpG86-561  in Control cells are 6.78 x 10-3  and 7.20 938 
x 10-3, respectively. p-values for GFP verses KHNYN-1 and KHNYN-2 for HIV-939 
1EnvCpG86-561  in ZAP-G1 cells are 3.22 x 10-1 and  5.33 x 10-1, respectively. RNA was 940 
extracted from cell lysates (B) and media (C) and genomic RNA (gRNA) abundance 941 
was quantified by qRT-PCR. The bar charts show the average value of five 942 
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independent experiments normalized to the value obtained for HeLa Control CRISPR 943 
cells co-transfected with pHIV-1 and pGFP-GFP. Data are represented as mean ± SD. 944 
*p < 0.05 as determined by a two-tailed unpaired t-test. For HIV-1EnvCpG86-561 genomic 945 
RNA in Control cell lysates, the GFP verses KHNYN-1 and KHNYN-2 p-values are 946 
2.14 x 10-2 and 2.30 x 10-2, respectively.  For HIV-1EnvCpG86-561 genomic RNA in ZAP-947 
G1 cell lysates, the GFP verses KHNYN-1 and KHNYN-2 p-values are 1.01 x 10-1 and 948 
4.33 x 10-2, respectively. For HIV-1EnvCpG86-561 genomic RNA in Control cell media, p-949 
values for GFP verses KHNYN-1 and KHNYN-2 are 8.97 x 10-4 and 9.38 x 10-4, 950 
respectively. For HIV-1EnvCpG86-561 genomic RNA in ZAP-G1 cell media, p-values for 951 
GFP verses KHNYN-1 and KHNYN-2 are 6.09 x 10-1  and 1.87 x 10-1, respectively. 952 
 953 
Figure 5. TRIM25 is required for KHNYN to inhibit HIV-1 with clustered CpG 954 
dinucleotides. 955 
 (A-B) HeLa Control CRISPR cells or TRIM25-G1 CRISPR cells were transfected with 956 
500 ng pHIV-1 or pHIV-1EnvCpG86-561 and 500 ng of pGFP-FLAG or 62.5 ng pKHNYN-957 
1-FLAG or pKHNYN-2-FLAG plus 437.5 ng of pGFP-FLAG. Culture supernatants from 958 
the cells were used to infect TZM-bl reporter cells (A). The bar charts show the 959 
average value of three independent experiments normalized to the value obtained for 960 
HeLa Control CRISPR cells co-transfected with pHIV-1 and pGFP-FLAG. Data are 961 
represented as mean ± SD. *p < 0.05 as determined by a two-tailed unpaired t-test. p-962 
values for GFP verses KHNYN-1 and KHNYN-2 for HIV-1EnvCpG86-561 in Control cells 963 
are 8.95 x 10-4 and 5.42 x 10-4, respectively. p-values for GFP verses KHNYN-1 and 964 
KHNYN-2 for HIV-1EnvCpG86-561 in TRIM25-G1 CRISPR cells are 1.78 x 10-3 and 1.01 x 965 
10-4, respectively. Gag expression in the media as well as Gag, Hsp90, Env, Actin, 966 
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KHNYN-FLAG and GFP-FLAG expression in the cell lysates was detected using 967 
quantitative immunoblotting (B).  968 
(C) Lysates of Control and TRIM25 CRISPR HEK293T cells transfected with pGFP-969 
FLAG, pKHNYN-1-FLAG or pKHNYN-2-FLAG were immunoprecipitated with an anti-970 
FLAG antibody. Post-nuclear supernatants and immunoprecipitation samples were 971 
analyzed by immunoblotting for HSP90, KHNYN-FLAG, TRIM25 and ZAP. The blots 972 
are representative of two independent experiments. 973 
(D) Lysates of Control and ZAP CRISPR HEK293T cells transfected with pGFP-FLAG, 974 
pKHNYN-1-FLAG or pKHNYN-2-FLAG were immunoprecipitated with an anti-FLAG 975 
antibody. Post-nuclear supernatants and immunoprecipitation samples were analyzed 976 
by immunoblotting for HSP90, KHNYN-FLAG, TRIM25 and ZAP. * indicates a non-977 
specific band. The blots are representative of two independent experiments. 978 
 979 
Figure 6. The KH and NYN domains are necessary for KHNYN antiviral activity. 980 
(A) Schematic of KHNYN-1 and KHNYN-2 domains and mutations in the NYN domain.  981 
(B-C)  HeLa cells were transfected with 500 ng pHIV-1 or pHIV-1EnvCpG86-561 and either 982 
500 ng of pGFP-FLAG or 62.5 ng pKHNYN-1/2-FLAG and 437.5 ng of pGFP-FLAG. 983 
Culture supernatants were used to infect TZM-bl reporter cells to measure infectivity 984 
(B). The bar charts show the average values of three independent experiments 985 
normalized to the value obtained for HeLa cells co-transfected with pHIV-1 and pGFP-986 
FLAG. Data are represented as mean ± SD. *p < 0.05 as determined by a two-tailed 987 
unpaired t-test. p-values for KHNYN-1 versus ΔKH-KHNYN-1, D443N-KHNYN-1, and 988 
D524A/D525A-KHNYN-1 for HIV-1EnvCpG86-561  are 1.31 x 10-2, 5.22 x 10-3, and 1.26 x 989 
10-3, respectively. p-values for KHNYN-2 versus ΔKH-KHNYN-2, D443N-KHNYN-2, 990 
and D524A/D525A-KHNYN-2 for HIV-1EnvCpG86-561 are 2.88 x 10-2 , 3.26 x 10-2, and 991 
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2.56 x 10-4, respectively. Gag expression in the media as well as Gag, Hsp90, Env, 992 
Actin, KHNYN-1/2-FLAG and GFP-FLAG expression in the cell lysates was detected 993 
using quantitative immunoblotting (C). See also Figure 6–figure supplement 1 and 2. 994 
 995 
Figure 7. KHNYN depletion increases infectious virus production for HIV-1 with 996 
clustered CpG dinucleotides and MLV Gag expression.  997 
(A) 100 ng pKHNYN-1-FLAG, pKHNYN-2-FLAG, pKHNYN-1-FLAG with a mutation in 998 
the PAM that prevents it from being targeted by KHNYN guide 1 (pKHNYN-1-CRG1-999 
FLAG) or pKHNYN-2-CRG1-FLAG plus 400 ng of pGFP were transfected into HeLa 1000 
Control CRISPR cells, KHNYN guide 1 (KHNYN-G1) CRISPR bulk cells or KHNYN-1001 
G1 CRISPR single cell clones A and B. KHNYN-FLAG abundance was measured by 1002 
quantitative western blotting.  1003 
 (B-C) HeLa Control CRISPR cells, ZAP-G1 CRISPR cells, KHNYN guide 1 (KHNYN-1004 
G1) CRISPR bulk cell population or single cell clones A and B were transfected with 1005 
500 ng pHIV-1 or pHIV-1EnvCpG86-561 and 500 ng pGFP. Culture supernatants were 1006 
used to infect TZM-bl reporter cells to measure infectivity (B). The bar charts show the 1007 
average value of six independent experiments normalized to the value obtained for 1008 
HeLa Control CRISPR cells co-transfected with pHIV-1 and pGFP. Data are 1009 
represented as mean ± SD. *p < 0.05 as determined by a two-tailed unpaired t-test. p-1010 
values for HIV-1EnvCpG86-561 in Control cells versus ZAP-G1, KHNYN-G1 Bulk, KHNYN-1011 
G1 Clone A, and KHNYN-G1 Clone B CRISPR cells are 8.23 x 10-6, 2.81 x 10-6, 1.60 1012 
x 10-6, and 2.24 x 10-6, respectively. Gag expression in the media as well as Gag, 1013 
Hsp90, Env, and Actin expression in the cell lysates was detected using quantitative 1014 
immunoblotting (C).  1015 
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(D-E)  HeLa Control CRISPR cells, ZAP-G1 CRISPR cells and KHNYN G1 CRISPR 1016 
clone B were transfected with 650 ng pMLV,  250ng p2.87 Vpu and 100 ng pGFP. 1017 
Gag expression in the media (D) as well as Gag and Hsp90 expression in the cell 1018 
lysates (E) was detected using quantitative immunoblotting. The bar charts show the 1019 
average value of five independent experiments normalized to the value obtained for 1020 
HeLa Control CRISPR cells. Data are represented as mean ± SD. *p < 0.05 as 1021 
determined by a two-tailed unpaired t-test. p-values for virions from Control cells 1022 
versus ZAP-G1 and KHNYN-G1 Clone B CRISPR cells without type I IFN are 1.28 1023 
x10-3 and 1.50 x10-3, respectively, and 4.17 x10-3 and 1.92 x10-2 with type I IFN 1024 
treatment. p-values for the cell lysates from Control cells versus ZAP-G1 and KHNYN-1025 
G1 Clone B CRISPR cells are 1.78 x10-2 and 8.01 x10-3 without type I interferon, 1026 
respectively, and 6.37 x10-2 and 1.73 x10-4 with type I interferon treatment. 1027 
 1028 
Figure 8. KHNYN is necessary for CpG dinucleotides to inhibit HIV-1 genomic 1029 
RNA expression.  1030 
(A-C) HeLa Control CRISPR cells, ZAP-G1 CRISPR cells, KHNYN-G1 CRISPR bulk 1031 
cells or 2 independent clones were transfected with 500 ng pHIV-1 or pHIV-1EnvCpG86-1032 
561 and 500 ng pGFP-FLAG. RNA was extracted from cell lysates (A-B) and media 1033 
(C). Genomic RNA (gRNA) (A, C) or nef mRNA (B) abundance was quantified by qRT-1034 
PCR. The bar charts show the average value of three independent experiments 1035 
normalized to the value obtained for HeLa Control CRISPR cells co-transfected with 1036 
pHIV-1 and pGFP-FLAG. Data are represented as mean ± SD. *p < 0.05 as 1037 
determined by a two-tailed unpaired t-test. p-values for HIV-1EnvCpG86-561 genomic RNA 1038 
in Control cell versus ZAP-G1, KHNYN-G1 Bulk, KHNYN-G1 Clone A, and KHNYN-1039 
G1 Clone B CRISPR cell lysates are 2.98 x 10-2, 3.70 x 10-2, 4.26 x 10-2, and 1.30 x 1040 
 44 
10-4, respectively.  p-values for HIV-1EnvCpG86-561 nef mRNA in Control cell versus ZAP-1041 
G1, KHNYN-G1 Bulk, KHNYN-G1 Clone A, and KHNYN-G1 Clone B CRISPR cell 1042 
lysates are 0.29, 0.54, 0.90 and 0.42, respectively. p-values for HIV-1EnvCpG86-561 1043 
genomic RNA in Control cell versus ZAP-G1, KHNYN-G1 Bulk, KHNYN-G1 Clone A, 1044 
and KHNYN-G1 Clone B CRISPR cell media are 1.65 x 10-2, 8.64 x 10-3, 2.82 x 10-3 , 1045 
and 3.54 x 10-4, respectively.  1046 
 1047 
Figure 9. Deletion of the KH-like domain or mutations in the NYN domain in 1048 
KHNYN prevent reconstitution of CpG-dependent inhibition of HIV-1 infectious 1049 
virus production in KHNYN CRISPR cells.  1050 
(A-B) HeLa KHNYN-G1 CRISPR clone B cells were transfected with 500 ng pHIV-1 1051 
or pHIV-1EnvCpG86-561 and 500 ng of pGFP-FLAG or 31.25 ng, 62.5 ng, 125 ng, 250 ng 1052 
or 500 ng of pKHNYN-1-CRG1-FLAG or pKHNYN-2-CRG1-FLAG plus the amount of 1053 
pGFP-FLAG required to make 500 ng total. Culture supernatants from the cells were 1054 
used to infect TZM-bl reporter cells (A). Each point shows the average value of three 1055 
independent experiments normalized to the value obtained for HeLa Control CRISPR 1056 
cells co-transfected with pHIV-1 and pGFP. Data are represented as mean ± SD. Gag 1057 
expression in the media as well as Gag, Hsp90, Env, Actin, KHNYN-FLAG and GFP-1058 
FLAG expression in the cell lysates was detected using quantitative immunoblotting 1059 
(B). 1060 
(C-D) HeLa KHNYN-G1 CRISPR clone B cells were transfected with 500 ng pHIV-1 1061 
or pHIV-1EnvCpG86-561, 468.75 ng of pGFP-FLAG and 31.25 ng of pKHNYN-1-CRG1-1062 
FLAG expressing either wild type or mutant proteins. Culture supernatants from the 1063 
cells were used to infect TZM-bl reporter cells (C). Each point shows the average value 1064 
of seven independent experiments normalized to the value obtained for HeLa Control 1065 
 45 
CRISPR cells co-transfected with pHIV-1 and pGFP. Data are represented as mean 1066 
± SD. *p < 0.05 as determined by a two-tailed unpaired t-test. p-values for HIV-1067 
1EnvCpG86-561 with KHNYN-1-CRG1 versus ΔKH-KHNYN-1-CGR1, D443N-KHNYN-1-1068 
CGR1 and D524A/D525A-KHNYN-1-CGR1 are 2.56 x 10-5, 1.95 x 10-4, and 2.12 x 10-1069 
4. respectively. Gag expression in the media as well as Gag, Hsp90, Env, Actin, 1070 
KHNYN-FLAG and GFP-FLAG expression in the cell lysates was detected using 1071 
quantitative immunoblotting (D). 1072 
 1073 
SUPPLEMENTAL FIGURE LEGENDS  1074 
Figure 2–figure supplement 1. HIV-1EnvCpG86-561 contains 36 introduced CpG 1075 
dinucleotides.  1076 
MacVector ClustalW alignment of nucleotides 1-600 of env from wild type HIV-1 and 1077 
HIV-1EnvCpG86-561. CpG dinucleotides introduced through synonymous mutations are 1078 
highlighted in red.   1079 
 1080 
Figure 6–figure supplement 1. KHNYN mutant proteins localize to the 1081 
cytoplasm. 1082 
Panels show representative fields for the localization of KHNYN-1/2-FLAG wild type 1083 
or mutant proteins in 293T Control CRISPR cells. Cells were stained with an anti-1084 
FLAG antibody (red) and DAPI (blue). The scale bar represents 10 µm. 1085 
 1086 
Figure 6–figure supplement 2. NYN domain alignment. 1087 
(A) MacVector ClustalW alignment of the NYN domains from KHNYN and ZC3H12A. 1088 
The amino acid identity and similarity is shown. The four aspartic acid residues that 1089 
coordinate the magnesium ion in the active site are highlighted in red.  1090 
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(B) MacVector ClustalW alignment of NYN domains from KHNYN, N4BP1, ZC3H12A, 1091 
ZC3H12B, ZC3H12C, ZC3H12D and MARF1. The four aspartic acid residues that 1092 
coordinate the magnesium ion in the active site are highlighted in red.  1093 
 1094 
Figure 7—figure supplement 1. KHNYN is necessary for CpG dinucleotides to 1095 
inhibit HIV-1 infectious virus production.  1096 
(A) 100 ng pKHNYN-1-FLAG, pKHNYN-2-FLAG, pKHNYN-1-FLAG with a mutation in 1097 
the PAM that prevents it from being targeted by KHNYN guide 2 (pKHNYN-1-CRG2-1098 
FLAG) or pKHNYN-2-CRG2-FLAG plus 400 ng pGFP were transfected into HeLa 1099 
Control CRISPR cells, KHNYN guide 2 (KHNYN-G2) CRISPR bulk cells or KHNYN-1100 
G2 CRISPR single cell clones A and B. KHNYN-FLAG abundance was measured by 1101 
quantitative immunoblotting.  1102 
(B-C) HeLa Control CRISPR cells, KHNYN-G2 CRISPR bulk cells or KHNYN-G2 1103 
CRISPR single cell clones A and B were transfected with 500 ng pHIV-1 or pHIV-1104 
1EnvCpG86-561 and 500 ng pGFP. Culture supernatants were used to infect TZM-bl 1105 
reporter cells to measure infectivity (B). The bar charts show the average value of 1106 
three independent experiments normalized to the value obtained for HeLa Control 1107 
CRISPR cells co-transfected with pHIV-1 and pGFP. Data are represented as mean 1108 
± SD. *p < 0.05 as determined by two-tailed unpaired t-test. p-values for HIV-1EnvCpG86-1109 
561 in Control cells versus KHNYN-G2 Bulk, KHNYN-G2 Clone A, and KHNYN-G2 1110 
Clone B CRISPR cells are 7.98 x 10-3, 1.49 x 10-2, and 3.44 x 10-2, respectively. Gag 1111 
expression in the media as well as Gag, Hsp90, Env, and Actin expression in the cell 1112 
lysates was detected using quantitative immunoblotting (C). 1113 
 1114 
Figure 7—figure supplement 2. CRISPR-Cas9-induced mutations in KHNYN.  1115 
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(A-B) The nucleotide sequence surrounding the guide RNA sequence for KHNYN 1116 
guide 1 (A) and KHNYN guide 2 (B). The sequence in the parental cells not transduced 1117 
with lentiCRISPRv2 (untransduced) as well as lentiCRISPRv2 expressing a guide 1118 
RNA targeting luciferase (Control), the bulk population of cells expressing either 1119 
KHNYN guide 1 or guide 2 as well as two single cell clones from each bulk population.  1120 
The numbers to the right of each sequence represent the frequency that the sequence 1121 
was identified in the total number of sequences for the specific cell line. 1122 
 1123 
Figure 7—figure supplement 3. KHNYN depletion does not substantially 1124 
increase Sindbis virus replication.  1125 
(A-B) HeLa Control CRISPR cells, ZAP-G1 CRISPR cells, TRIM25 CRISPR cells and 1126 
KHNYN-G1 CRISPR clone B were infected with Sindbis virus and the amount of 1127 
infectious virus was measured in the cell supernatants 8, 16, 24 and 32 hours post-1128 
infection.  (A) The relative amount of infectious virus at 24 hours. The bar chart shows 1129 
the average value of three independent experiments normalized to the value obtained 1130 
for HeLa Control CRISPR cells. Data are represented as mean ± SD. (B) The three 1131 
independent Sindbis virus replication curves. 1132 
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